跳至主要内容
临床试验/NCT02142114
NCT02142114Unknown早期 1 期

Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles

Retina Health Center2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2014年5月1日最近更新:
适应症

试验速览

阶段
早期 1 期
发起方
入组人数
200
试验地点
2
主要终点
Pain assessment.

研究概览

简要总结

The purpose of this study is to determine if a smaller needle size reduces discomfort suffered by patients both during and following intravitreal injections. It is the investigators belief that using a smaller size needle will help patients to be less fearful of intravitreal injections and more amenable to treatment. This study will also evaluate the effect of needle size on post injection intraocular pressure, to see if smaller needles may reduce wound leak and increase the intraocular pressure following injection.

The investigators hypothesize that subject eyes injected with the smaller size needle will result in greater patient comfort both during and after their injection as compared to the eye injected with the larger needle. The investigators objective is to reduce any discomfort felt by patients who receive intravitreal injections. The investigators also hypothesize that the smaller needle will result in higher post injection pressures, and another objective is to determine if this can affect patient comfort and increase the risk of glaucomatous optic nerve damage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Health Services Research
盲法
Double (Participant, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Subject's normal therapeutic regimen calls for them to receive two sessions of bilateral injections of the same volume of ranibizumab within the next year.
  • Disease related considerations: None.
  • Other considerations: Subjects who must be able to report pain scores during and up to 48 hours following an intravitreal injection. Also, subjects must consent to at least 5 intraocular pressure checks per eye for each injection procedure.

排除标准

  • Pregnancy (positive pregnancy test) or lactation
  • Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch.
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • special classes of subjects (vulnerable subjects), such as fetuses, pregnant women, children, institutionalized mentally disabled, or others, especially those whose ability to give voluntary informed consent may be in question.

结局指标

主要结局

Pain assessment.

时间窗: Immediately following an injection and follow-up within 48 hours of the injection.

Following each session of injections, the patient will be asked to fill out a short questionnaire regarding the comfort levels of the two needle sizes. Also, all subjects will be followed up by phone within 48 hours to assess any post-injection pain.

次要结局

  • Intraocular pressure assessment(1 minute prior, as well as 1, 3, 10, and 30 minutes post-injection)

研究者

发起方
Retina Health Center
申办方类型
Industry
责任方
Principal Investigator
主要研究者

Alexander Eaton

Principal Investigator

Retina Health Center

研究点 (2)

Loading locations...

相似试验

Assessment of Comfort Level Following an... | 临床试验